Stockscreener 앱 받기
129.86
0.05%
-0.07
시장 영업 전:
130.50
0.64
+0.49%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PR Newswire
Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada
Barclays Increases Stake in Neurocrine Biosciences - National Today
American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today
Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir
Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com
Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today
GW&K Investment Management LLC Sells 17,980 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Segall Bryant & Hamill LLC - MarketBeat
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Strong Buy Ratings and 33.92% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Stock Position Lowered by TD Asset Management Inc - MarketBeat
Rafferty Asset Management LLC Sells 20,445 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risk Check: Why is Neurocrine Biosciences Inc stock going up2025 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
DNB Asset Management AS Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Yahoo Finance UK
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Primecap Management Co. CA - MarketBeat
Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C. - MarketBeat
Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)? - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Wolfe Research - MarketBeat
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline - Investing.com Australia
Citigroup Inc. Lowers Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Reports Q4 Earnings Miss Amid Strong Sales Growth - Intellectia AI
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential - Investing.com Australia
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - The AI Journal
Neurocrine plans March fireside chats at TD Cowen and Leerink - Stock Titan
Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline By Investing.com - Investing.com Canada
Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential By Investing.com - Investing.com India
Investment Review: Is Neurocrine Biosciences Inc a strong growth stockWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Wolfe Research Begins Coverage on Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Wolfe Research Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation - Nasdaq
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation After Positive Analyst Views And 2026 Guidance - simplywall.st
Neurocrine (NBIX) Chief Scientific Officer gifts 3,110 company shares - Stock Titan
Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update - Insider Monkey
Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update - Finviz
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Vanguard Group Inc. Decreases Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Position Trimmed by Persistent Asset Partners Ltd - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp - MarketBeat
Aberdeen Group plc Reduces Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Cut to “Strong Sell” at Zacks Research - Defense World
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
5.37%
0.83%
자본화:
|
볼륨(24시간):